... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Breast neoplasms HER2 ERBB2 protein Human Neoadjuvant therapy Trastuzumab Despite these remarkable...

...Chang Ik Yoon; Suyon Chang; Jeaneum Park; Dooreh Kim; Young Joo Lee; Soo Youn Bae; Woo-Chan Park Background: In human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer, prediction of trastuzumab-related cardiac toxicity remains a challenge. The coronary calcium artery...

...Christoph Suppan; Marija Balic Background: Approximately 20% of all breast cancer cases show overexpression or amplification of the human epidermal growth factor receptor 2 (Her2) [Cancer Epidemiol Biomarkers Prev. 2017;26(4):632–41]. With the introduction of trastuzumab, lapatinib, and pertuzumab...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. ASCO Palbociclib Sacituzumab Trastuzumab...

...Naoko Iwamoto; Tomoyuki Aruga; Shinichiro Horiguchi All the patients received adjuvant HER2-targeted therapy (trastuzumab and/or pertuzumab). Of the 135 patients, six (4.4%) received the combination of pertuzumab and trastuzumab. Trastuzumab was given every 3 weeks (8 mg/kg loading dose...

... treated with anti-HER2 treatments compared to patients who were naïve to anti-HER2 agents. Methods: We conducted a retrospective observational study of HER2-positive MBC patients who were treated with trastuzumab and pertuzumab from 2014 to 2018. We collected and analyzed data including patients...

... for supportive therapy were the pioneers; now, monoclonal antibody biosimilars are conquering the market. In Europe, this is currently limited to biosimilars of the monoclonal antibodies trastuzumab and rituximab. However, the pipeline is full and several monoclonal antibody biosimilars in oncology are now...

...Xinguang Wang; Yingjian He; Zhaoqing Fan; Tianfeng Wang; Yuntao Xie; Jinfeng Li; Tao Ouyang Background: We sought to investigate the incremental benefit of trastuzumab in patients with HER2-positive breast cancer who achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT...

.... With the introduction of trastuzumab, a monoclonal antibody against HER2, survival has significantly improved in early and metastatic breast cancer. Trastuzumab's patent has now expired and biosimilars are moving into the market. Several clinical trials have led to the approval of 5 different biosimilar trastuzumabs...

... whether the prognosis for HER2-positive patients treated with adjuvant trastuzumab differs from that of HER2-negative patients. Methods: We performed a retrospective study including patients with lymph node-negative invasive breast cancer treated at our institution in the period 2000-2009. Disease-free...

..., Lyon, 2003, pp. 32-34. 7. Alkaied H, Harris K, Azab B, Dai Q: Primary neuroendocrine breast cancer, how much do we know so far? Med Oncol 2012;29:2613-2618. Neuroendocrine carcinoma Trastuzumab Breast carcinoma Breast cancer is one of the most frequent neoplasms...

...: This retrospective analysis was planned as a direct comparison of taxanes plus trastuzumab to the less toxic combination of oral vinorelbine (OV) plus trastuzumab as a first-line therapy for metastatic HER2-positive breast cancer. Patients and Methods: Patients (n = 76) receiving either taxanes (group A) or OV...

...Leonardo Gomes da Fonseca; Debora de Melo Gagliato; Tiago K. Takahashi; Milena Perez Mak; Romualdo Barroso-Sousa; Laura Testa; Vanessa Petry Helena; Romulo de Paula Costa; Paulo M. Hoff; Max S. Mano Background: Trastuzumab improves the survival of patients with human epidermal growth factor...

... breast cancer. However, both trastuzumab and anthracycline have cardiotoxicity, and it remains unclear how to use trastuzumab in combination with an anthracycline to curtail their cardiotoxicity. Patients and Methods: From 2010 to 2013, we administered weekly (q1w) paclitaxel (wP) followed by 75 mg/m 2...

...Thomas E. Delea; Carol Hawkes; Mayur M. Amonkar; Konstantinos Lykopoulos; Stephen R. D. Johnston Background: In the EGF30008 and TAnDEM (TrAstuzumab in Dual HER2 ER-positive Metastatic breast cancer) trials, anti-HER2 therapy plus an aromatase inhibitor (lapatinib + letrozole (LAP + LET...

...Ana Catarina Pinto; Evandro de Azambuja; Martine Piccart-Gebhart Trastuzumab administered in combination with various chemotherapy regimens has led to outstanding improvements in both disease-free survival and overall survival. So far, thousands of patients have been treated in this way which has...

... DFS were: peritumoral lymphatic invasion (L1) (p = 0.031), negative hormone receptor status (p = 0.003), non-use of hormonal therapy (p = 0.001), and a positive HER2 status (p = 0.003). Amongst the HER2-positive patients only 2.7% (n = 1/37) of those treated with trastuzumab had a DFS event compared...

...Darko Vucicevic; Elizabeth J. Carey; Nina J. Karlin Background: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are only 2 prior cases of trastuzumab-related hepatotoxicity reported in the literature...

..., in particular the pairing of the most potent signaling heterodimer HER2/HER3, thus providing a potent strategy for dual HER2 inhibition. It binds to the extracellular domain of HER2 at a different epitope than trastuzumab. Pertuzumab and trastuzumab act in a complementary fashion and provide a more complete...

...Christoph Uleer; Jasmin Yazdan-Pourfard; Bernhard Holland; Karl-Friedrich Bürrig; Christina Moisidis-Tesch; Gunter von Minckwitz Background: Since the introduction of trastuzumab into the treatment of Her-2/neu-positive metastatic breast cancer, cases of long-term survival have become more frequent...